New: Clinical trial search, funded by the National Cancer Institute
New: NCI-funded clinical trial search
Community
Tools
Company
Support
Sign in
Join for Free
Join for Free
Community
In what circumstance, if any, would you consider PARP inhibition in metastatic BRCA wild type TNBC who has exhausted all other treatment options?
Does LOH or VUS play a role in your decision?
Good Question
Save
Request Answers
Share
Add Answer
